Participants | 50 |
Age (average, range) | 24.18 (18–30 years) |
Ethnicity1 | |
White | 26 (52%) |
Aboriginal2 | 10 (20%) |
Latin American | 7 (14%) |
South Asian | 5 (10%) |
Southeast Asian | 2 (4%) |
Chinese | 2 (4%) |
Korean | 2 (4%) |
Filipino | 2 (4%) |
Arab/West Asian | 2 (4%) |
Black | 1 (2%) |
Japanese | 1 (2%) |
Other | 2 (4%) |
Gender3 | |
Cisgender man | 44 (88%) |
Transgender man | 4 (8%) |
Queer | 4 (8%) |
Genderqueer | 2 (4%) |
Non-binary | 1 (2%) |
Sexual orientation3 | |
Gay | 29 (58%) |
Bisexual | 14 (28%) |
Pansexual | 6 (12%) |
Queer | 4 (8%) |
Straight | 2 (4%) |
Asexual | 1 (2%) |
Unsure | 1 (2%) |
Other (incl. homoflexible) | 2 (4%) |
Opioid use | |
Non-opioid substance use Both opioid and non-opioid substance use4 | 40 (80%) 10 (20%) |
Substances used in the previous 12 months | |
Alcohol | 47 (94%) |
Cannabis | 41 (82%) |
MDMA | 25 (50%) |
Cocaine | 20 (40%) |
Poppers | 20 (40%) |
Mushrooms | 20 (40%) |
Meth | 18 (36%) |
Benzodiazepines Ketamine | 11 (22%) 11 (22%) |
Erectile dysfunction drugs | 10 (20%) |
GHB | 9 (18%) |
Speed | 9 (18%) |
T3s5 | 7 (14%) |
Crack | 5 (10%) |
Heroin | 5 (10%) |
Fentanyl | 4 (8%) |
Opioids6 | 4 (8%) |
LSD | 4 (8%) |
Methadone | 3 (6%) |
Steroids | 3 (6%) |
Ritalin | 1 (2%) |
Others7 | 8 (16%) |